Ethypharm licenses cardio product to Ranbaxy for Indian market

Mumbai, Sep 18 (UNI) Ethypharm India, subsidiary of leading French multinational drug delivery company Ethypharm S A, today announced out-licensing and supply contract agreements for a fixed dose combination of Fenofibrate micronized 160 mg and Atorvasratin 10 mg with Ranbaxy which will be launched in the Indian market.

This deal comes in quick succession after a similar deal with Ethypharm had signed with Ranbaxy for out-licensing and supply of Tramadol Flashtab in May this year.

The products will be supplied from Ethypharm's manufacturing facility near Mumbai as finished and packaged formulations and marketed and distributed by Ranbaxy under their brand name STORFIB.

In a statement here, Mr Ajey Kumar, Chief Executive Officer (CEO) of Ethypharm India said that,''Combinational products are growing very fast in India and it is estimated that more than two thirds of all combination products worldwide are registered first in India.Ethypharm endeavours to ensure that the benefit of its Drug Delivery technologies now also encompass such combination products.This product encapsulates the benefits of both Combination offerings and Drug Delivery technologies and will help the large Indian populace who suffer from Mixed Dyslipidemia which is a common culprit in the Asian subcontinent including India.'' Commenting on the agreement,Mr Sanjeev I.Dani,Regional Director, India and Middle East,Ranbaxy said, ''Ranbaxy in India is the leader in Novel Drug Delivery Systems (NDDS)products and a pioneer in the Lupids management portfolio as well STORFIB very aptly symbolises both of these strengths and would further augment our leadership position in the cardio-vascular market.'' UNI AR WD AG1558